Abstract: Disclosed is a method of remyelinating axons with 6-substituted estradiol compounds of the formula The methods can be used to treat a variety of demyelinating diseases.

Abstract: Disclosed is a method of remyelinating axons with 6-substituted estradiol compounds of the formula The methods can be used to treat a variety of demyelinating diseases.

Abstract: Disclosed herein are 6-substituted 13-demethyl-estradiol derivatives as selective ER? agonists. Also disclosed is a method for treating pain by administering these 6-substituted 13-demethyl-estradiol derivatives.

Abstract: Disclosed is a method of treating Alzheimer's Disease with 6-substituted estradiol compounds of the formula The methods can be used to treat a variety of diseases related to the up-regulation of lipoprotein lipase or apolipoprotein C2.

Abstract: Disclosed herein are 6-substituted 13-demethyl-estradiol derivatives as selective ER? agonists. Also disclosed is a method for treating pain by administering these 6-substituted 13-demethyl-estradiol derivatives.

Abstract: Disclosed herein are 6-substituted 13-demethyl-estradiol derivatives as selective ER? agonists. Also disclosed is a method for treating pain by administering these 6-substituted 13-demethyl-estradiol derivatives.

Abstract: Compositions and methods are provided for the clinical assessment, diagnosis, and treatment of multiple sclerosis. The compositions of the invention are molecules related to the 21.5 kDa fetal isoform of human myelin basic protein, and include nucleic acids and polypeptides. The nucleic acid molecules of the invention are useful in the efficient production of modified and unmodified 21.5 kDa myelin basic protein polypeptides, such polypeptides being useful for assaying T cells for responsiveness to myelin basic protein epitopes. The polypeptides of the invention are also useful as therapeutic agents that act by inducing T cell responses, including apoptosis, as a means of treating multiple sclerosis.

Abstract: Compositions and methods are provided for the clinical assessment, diagnosis, and treatment of multiple sclerosis. The compositions of the invention are molecules related to the 21.5 kDa fetal isoform of human myelin basic protein, and include nucleic acids and polypeptides. The nucleic acid molecules of the invention are useful in the efficient production of modified and unmodified 21.5 kDa myelin basic protein polypeptides, such polypeptides being useful for assaying T cells for responsiveness to myelin basic protein epitopes. The polypeptides of the invention are also useful as therapeutic agents that act by inducing T cell responses, including apoptosis, as a means of treating multiple sclerosis.

Abstract: Collections of animals useful for evaluating effects of test agents are disclosed. The collections of animals are offspring of combinatorially mated inbred animals designed to maximize genetic diversity at selected genetic loci or across the genome.

Abstract: The use of anti-C5 antibodies, e.g., monoclonal antibodies, to treat glomerulonephritis (GN) is disclosed. The administration of such antibodies at low dosage levels has been found to significantly reduce glomerular inflammation/enlargement and other pathologic conditions associated with GN. Also disclosed are anti-C5 antibodies and anti-C5 antibody-encoding nucleic acid molecules. These antibodies are useful in the treatment of GN and other inflammatory conditions involving pathologic activation of the complement system.

Abstract: A Thermococcus barosii DNA polymerase with reduced 3'-5' exonuclease activity is disclosed. Additionally disclosed is a Thermococcus barosii DNA polymerase with increased ability to incorporate ribonucleotides and dideoxynucleotides.